AzTrials
AzTrials

Hepatocellular CarcinomaNCT02147301

TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve

A study testing LC Bead in people with Hepatocellular Carcinoma and Chemoembolization, run by University of California, San Francisco at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

TACE is frequently offered to patients with baseline hepatic dysfunction with the purpose of diminishing hepatic tumor burden while patients await transplantation. Without this therapeutic measure, disease may progress beyond UNOS T2 criteria required for organ allocation. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Hepatocellular Carcinoma, Chemoembolization
What is being tested?
LC Bead
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
17 participants
Where
1 siteUnited States
Study dates
17 Dec 2014to 5 Apr 2017
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult male or female patients, age 18 years of age or older
  • Diagnosis of liver-only HCC based on European Association for the Study of the Liver (EASL) criteria (radiographic lesion appearance on contrast-enhanced CT or MRI, i.e. enhancement on early arterial phase, washout on portal venous phase with or without associated elevation of serum alpha-fetoprotein (AFP) level >200 Units Per Millilitre (U/ml)) or histologic confirmation of HCC diagnosis, whichever is applicable.
  • UNOS stage T1, T2, or T3 disease.
  • Candidates for liver transplantation (listed or screened) according to one of the following criteria:
  • Milan criteria (one lesion < 5cm or 3 or fewer lesions each < 3cm),
  • UCSF Downstaging criteria (one lesion less than 8 cm or 2-3 lesions each less than 5 cm with sum of maximum dimensions less than 8 cm, or 4-5 lesions each less than 3 cm with sum of maximum dimensions less than 8 cm)
Show all 17Show fewer
  • University of California, San Francisco (UCSF) All-Comers criteria (UNOS stage T3 disease beyond UCSF Downstaging Criteria).
  • At least one measurable site of disease in the liver according to RECIST version 1.1 and odified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria.
  • At least one of the following clinical, laboratory, or imaging parameters:
  • Mild or moderate ascites
  • Serum bilirubin ≥ 3 mg/dl but less than 6 mg/dl
  • Aspartate aminotransferase (AST) > 5 times upper limit of normal (ULN) but < 10 times ULN
  • Alanine aminotransferase (ALT) > 5 times upper limit of normal (ULN) but < 10 times ULN
  • International normalized ratio for prothrombin time (INR) >1.5 but ≤ 2.5
  • Portal vein thrombosis (branch or main)
  • Functioning transjugular intrahepatic portosystemic shunt (TIPS) or surgical portosystemic shunt
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

Who cannot join

  • Liver-directed therapy (chemoembolization, radioembolization, bland embolization, ablative therapy) within 4 weeks of DEB-TACE.
  • Previous liver transplantation.
  • Serum bilirubin ≥ 6 mg/dl
  • AST > 10 times upper normal limit
  • ALT > 10 times upper normal limit
  • INR > 2.5
Show all 24Show fewer
  • Serum creatinine > 1.5 mg/dl
  • Macrovascular tumor invasion of portal and/or hepatic vein(s)
  • Extracapsular tumor extension
  • Extrahepatic disease
  • Hepatic encephalopathy refractory to medical therapy
  • Active uncontrolled infection
  • Imaging evidence of common bile duct obstruction
  • Previous sphincterotomy or bilio-enteric anastomosis
  • Significant hepatic arterial to portal vein shunting in the area to be treated.
  • Symptomatic congestive heart failure (CHF)
  • Allergy to or intolerance of prior doxorubicin-based TACE
  • Allergy to or intolerance to iodinated contrast media despite standard of care pre-medication
  • Any contraindications to treatment with LC Bead™ device (e.g. patients with large diameter arteriovenous shunts or patients with a right-to-left shunt).
  • Systemic therapy with sorafenib or other systemic chemotherapeutic agent(s) less than 1 week prior to first planned DEB-TACE.
  • Active second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ. (Patients with history of malignancy are not considered to have a "currently active" malignancy if they have completed therapy and are now considered by their physician to be at less than 30% risk for relapse.)
  • Uncontrolled intercurrent illness including, but not limited to: Ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, uncontrolled peripheral vascular disease, myocardial infarction within preceding 12 months, cerebrovascular accident within preceding 12 months, pulmonary disease impairing functional status or requiring oxygen, impairment in gastrointestinal function that may affect or alter absorption of oral medications (such as malabsorption or history of gastrectomy or bowel resection).
  • Pregnant or lactating women are excluded from this study because of the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with DEB-TACE, breastfeeding must be discontinued for eligibility.
  • Psychiatric illness, other significant medical illness, or social situation which, in the investigator's opinion, would limit compliance or ability to comply with study requirements.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • University of California San Francisco

    San Francisco, California, 94143

Other trials in United States

About this study

Official title: Prospective Phase II Study of Chemoembolization With Doxorubicin-Eluting Microspheres for Liver Transplantation Candidates With Hepatocellular Carcinoma and Marginal Hepatic Reserve

TACE is frequently offered to patients with baseline hepatic dysfunction with the purpose of diminishing hepatic tumor burden while patients await transplantation. Without this therapeutic measure, disease may progress beyond UNOS T2 criteria required for organ allocation.

The purpose of the study is to determine whether transarterial chemoembolization using doxorubicin-eluting beads (DEB-TACE) can be used safely and effectively to treat patients with liver-only hepatocellular carcinoma (HCC) and baseline hepatic dysfunction.

Being tested
LC Bead
Medical subject headings
Carcinoma, Hepatocellular

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LC BeadDevice

    Also called DC Bead

    Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):

    Doxorubicin-loaded LC Beads® are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first.

Study groups in NCT02147301
Study groupRoleWhat they receive
DEB-TACEExperimentalDoxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE): Doxorubicin-loaded LC Beads® are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first
Receives: Device: LC Bead

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Best Observed Radiographic Response Rate (Measured by mRECIST)

    Best observed radiographic response rate to Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE) by modified Response Evaluation Criteria in Solid Tumors (mRECIST) was defined as number of patients who had CR, PR, or SD as their best observed response divided by total number of patients with at least one available CT or MRI. Definition of mRECIST for Hepatocellular Carcinoma (HCC). Complete response (CR) = Disappearance of any intratumoral arterial enhancement in all target lesions. Partial response (PR)=At least a 30% decrease in sum of diameters of viable (enhancement in arterial phase) target lesions, taking as reference baseline sum of diameters of target lesions. Stable disease (SD)=Any cases that do not qualify for either partial response or progressive disease. Progressive disease (PD)=An increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enh

    Measured: 1 year

  2. Number of Patients Who Developed New Severe Adverse Events

    Number of patients who developed new severe adverse events according to NCI CTCAE version 4.0

    Measured: 1 year

Secondary outcomes (8)

  1. Best Observed Objective Radiographic Response by mRECIST

    Best observed objective radiographic response was defined as the number of patients who had a complete response or partial response divided by total number of evaluable patients.

    Measured by mRECIST (see mRECIST definition in the description of the primary objective).

    Measured: 6 months

  2. Time to Untreatable Progression (TTUP)

    TTUP is defined as time (months) from the first on-study DEB-TACE to development of radiographic disease progression untreatable by liver-directed percutaneous or surgical methods (by mRECIST).

    Measured: 1 year

  3. Time to Progression (TTP)

    Time to progression was defined as the period of time from the first on-study DEB-TACE to radiographic disease progression at any site by mRECIST.

    Measured: 1 year

  4. Time to Hepatic Progression (TTHP)

    Time to hepatic progression (TTHP) was defined as a period of time from the first on-study DEB-TACE till development of radiographic evidence of disease progression in the liver by mRECIST.

    Measured: 1 year

  5. Progression Free Survival (PFS) Rate

    Progression free survival rate was defined as the number of patients who were alive and free from radiographic progression by mRECIST at pre-defined time periods.

    PFS rate was calculated at 3 months, 6 months, 12 months, and 24 months

    Measured: 3 months, 6 months, 12 Months, and 24 months

  6. Proportion of Patients With Alpha-fetoprotein (AFP) Response With ≥ 50% Decline From Baseline

    This measure was defined as the number of patients with alpha-fetoprotein (AFP) response with ≥ 50% decline from baseline (in patients with baseline level ≥ 20) after DEB-TACE.

    Measured: 1 year

  7. Left Ventricular Ejection Fraction (LVEF)

    Left ventricular ejection fraction (LVEF) was measured as percent contraction prior to the first DEB-TACE and 1 month following last planned DEB-TACE. Median LVEF and full range were reported.

    Measured: Baseline, 1 month following last planned DEB-TACE

  8. Median Area Under Curve (AUC)

    Area under curve for doxorubicin concentration in the serum over 7 days was measured by obtaining serum doxorubicin concentration samples at predose, 5 min, 20 min, 40 min, 60 min, 120 min, 6 hours, 24 hours, 7 days time points. A graph of serum doxorubicin concentration over time was then plotted for each of the 17 patients, and the area under the curve for each of the 17 patients was calculated.

    Pharmacokinetic sampling was performed only during each of the first planned DEB-TACE procedures.

    Measured: 7 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 May 2014 (estimated)
  2. Study start17 Dec 2014
  3. Primary completion27 Jan 2017
  4. Study completion5 Apr 2017

Why it stopped: Risk to benefit ratio is not acceptable

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
17 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02147301
Sponsor's protocol ID
124520
Status last verified
Aug 2019
First submitted
19 May 2014
Last updated
10 Sep 2019
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing LC Bead in people with Hepatocellular Carcinoma and Chemoembolization, run by University of California, San Francisco at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 17 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 10 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 10 Sep 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Best Observed Radiographic Response Rate (Measured by mRECIST) (time frame: 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02147301.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2019.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in